Soy isoflavone treatment was reported to reduce the number of severe asthma exacerbations in patients with the high plasminogen activator inhibitor-1(PAI-1)-producing genotype of asthma, and PAI-1 polymorphisms were suggested as a genetic biomarker for soy isoflavone-responsive asthma [243]. The gene discussed is SERPINE1; the disease is asthma.